In conducting negotiations, CEPS also takes into consideration
the necessary levels of healthcare investment, any requisite changes to screening programmes, the organisation
of care, requirements for monitoring and dissemination of
the technology and adjustments to the regulatory framework. In the course of the negotiations, the Association
of Pharmaceutical Industry (Les Entreprises du Médicament,
LEEM), which represents the interests of the French pharmaceutical industry, also plays a role.